Clinical trials: Chemoradiation
Cervical Cancer
FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)
Nearly all cervical cancers are caused by the human papilloma virus (HPV), which can be detected in cancer tissue by laboratory tests.
- Trial name
- HPVDNA02 (NCT03853915)
- Testing
- [18-F]- FDG - PET
- Where
- Canada
- Volunteers
- 64 people
- Sponsor
- University Health Network, Toronto
Nasopharyngeal Carcinoma, PD-1 Inhibitors
PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial
programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival (PFS) and overall survival (OS) was still…
- Conditions
- Nasopharyngeal Carcinoma, PD-1 Inhibitors, Chemoradiotherapy
- Trial name
- NCT05520814
- Testing
- PD-1 inhibitors, chemoradiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Bladder Cancer
Chemoradiotherapy for Recurrent T1G3 Bladder Cancer
To evaluate the short term results of chemoradiation in case of T1G3 BC after BCG failure.
- Trial name
- NCT03274284
- Testing
- chemoradiation
- Volunteers
- 20 people
- Sponsor
- Assiut University
Nasopharyngeal Carcinoma
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
The goal of this multicenter randomized non-inferior study is to compare the additon of camrelizumab or nimotuzumab to neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma…
- Trial name
- NCT05772208
- Testing
- Camrelizumab, Nimotuzumab, neoadjuvant chemotherapy and CCRT
- Where
- China
- Volunteers
- 459 people
- Sponsor
- Fudan University
Pancreatic Cancer
Chemoradiation in Locally Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00262951
- Testing
- recombinant interferon alfa, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Pancreatic Ductal Adenocarcinoma
Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy
Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. About 40% of pancreatic cancer patients were diagnosed as locally advanced unresectable status without distant metastasis.
- Trial name
- NCT02570529
- Testing
- Albis®
- Sponsor
- Yonsei University
Squamous Cell Carcinoma of the Head and Neck
Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection
Early detection of viable residual tumor or early neoplastic recurrence represents a real challenge in monitoring patients treated with concomitant chemoradiotherapy squamous cell carcinoma of the upper aerodigestive tract.
- Trial name
- TEPVAD (NCT02510872)
- Testing
- 18F-FDG PET combined with CT with iodinated contrast injection, 18F-FDG PET combined with CT without injection
- Where
- France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Caen
Anal Cancer
Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer
RATIONALE: Drugs used in chemotherapy, such as mitomycin, fluorouracil, and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00068744
- Testing
- cisplatin, fluorouracil, mitomycin C
- Where
- 24 sites in Belgium, Egypt and 5 more
- Volunteers
- 88 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00828009
- Testing
- bevacizumab, Tecemotide, carboplatin
- Where
- 88 sites in United States
- Volunteers
- 70 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Colorectal Neoplasms
Celebrex With Preoperative Chemoradiation - Rectal Cancer
Colorectal carcinoma is the third most common cause of death from cancer. Approximately, 30% of colorectal carcinomas involve the rectum.
- Trial name
- NCT00188565
- Testing
- Celecoxib
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- University Health Network, Toronto
Glioblastoma
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients with newly diagnosed glioblastoma receiving concurrent radiation and temozolomide.
- Trial name
- NCT05635734
- Testing
- Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
- Where
- 4 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Cantex Pharmaceuticals
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
In this study, participants with locally advanced rectal cancer patients will be treated according to MMR/MSI status. There will be two cohorts in this study: Cohort A and Cohort B.
- Trial name
- NCT04304209
- Testing
- Oxaliplatin, Capecitabine, Sintilimab
- Where
- China
- Volunteers
- 195 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small-Cell Lung
IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy
To investigate the impact of presence/absence or grade of radiation pneumonitis before starting IMFINZI, on the onset of interstitial lung disease (including radiation pneumonitis) after starting IMFINZI, in the real world in…
- Trial name
- NCT03643484
- Where
- 37 sites in Japan
- Volunteers
- 634 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer, Limited Stage, Hyperfractionated Accelerated Radiotherapy
Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer
Small cell lung cancer (SCLC) remains a challenging disease with poor prognosis and limited treatment options despite decades of research.
- Conditions
- Small Cell Lung Cancer, Limited Stage, Hyperfractionated Accelerated Radiotherapy, Simultaneous Radiotherapy and Chemotherapy
- Trial name
- NCT06784206
- Testing
- Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Cervical Cancer, Neoadjuvant Chemotherapy
Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer
This phase III randomized prospective clinical study was conducted to compare the short-term and long-term outcomes of gemcitabine and cisplatin neoadjuvant chemotherapy versus definite cisplatin weekly concurrent…
- Trial name
- NCT05189028
- Testing
- gemcitabine and cisplatin
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Chuangzhen Chen
Esophageal Squamous Cell Carcinoma (ESCC)
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
This is a prospective, open-label, randomized phase II clinical trial designed to compare the efficacy and toxicity of hypofractionated concurrent chemoradiotherapy versus conventional fractionated concurrent chemoradiotherapy…
- Trial name
- NCT06912074
- Testing
- Induction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.
It's a Phase Ib/II clinical trial to evaluate the efficacy and safety of TQB3728 tablets in sequential maintenance TQB2450 injection therapy in patients after sequential or concurrent chemoradiation for locally advanced non-small…
- Trial name
- NCT05859373
- Testing
- TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation, TQB2450 injection, sequential or concurrent chemoradiation
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chemoradiotherapy-Induced Severe Oral Mucositis
Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.
This study is being performed to evaluate the effectiveness of a new drug, clonidine HCl MBT, to prevent the onset of severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC) who are being treated with…
- Trial name
- VOICE (NCT04648020)
- Testing
- Clonidine HCl Mucoadhesive Buccal Tablet
- Where
- 74 sites in United States, France and 3 more
- Volunteers
- 190 people
- Sponsor
- Monopar Therapeutics
Extensive-stage Small Cell Lung Cancer
A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Etoposide-cisplatin/ -carboplatin in combination with PD-L1 inhibitor for 4 cycles followed by maintenance therapy with PD-L1 inhibitor is currently the world-wide first-line treatment for extensive-stage small cell lung cancer.
- Trial name
- NCT04636762
- Testing
- Radiation Therapy
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Second Xiangya Hospital of Central South University